Conformational HER-2/neu B-cell Epitope Peptide Vaccine Designed to Incorporate Two Native Disulfide Bonds Enhances Tumor Cell Binding and Antitumor Activities
Open Access
- 1 January 2005
- journal article
- Published by Elsevier in Journal of Biological Chemistry
- Vol. 280 (1) , 54-63
- https://doi.org/10.1074/jbc.m411020200
Abstract
No abstract availableKeywords
This publication has 42 references indexed in Scilit:
- An Alpha Helix Conformationally Restricted Peptide Is Recognized by Cervical Carcinoma Patients' SeraJournal of Medicinal Chemistry, 2003
- Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her‐2/neuInternational Journal of Cancer, 2003
- beta-Sheet is the bioactive conformation of the anti-angiogenic anginex peptideBiochemical Journal, 2003
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin FabNature, 2003
- Disabling Receptor Ensembles with Rationally Designed Interface PeptidomimeticsJournal of Biological Chemistry, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- A Structure-Based Approach to a Synthetic Vaccine for HIV-1Biochemistry, 2000
- Effects of interferons on the expression of the proto‐oncogene her‐2 in human ovarian carcinoma cellsInternational Journal of Cancer, 1992
- Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptorNature, 1986
- Tyrosine Kinase Receptor with Extensive Homology to EGF Receptor Shares Chromosomal Location with neu OncogeneScience, 1985